CureVac N.V.

CureVac N.V. is a global biopharmaceutical company focused on developing transformative medicines using messenger ribonucleic acid (mRNA) technology. mRNA is fundamental to protein production in living cells, and CureVac aims to enable the body to produce its own therapeutic proteins. The company's technology platform optimizes mRNA constructs to encode functional proteins that either trigger an immune response or replace missing or defective proteins. CureVac's product portfolio includes clinical and preclinical candidates across prophylactic vaccines, oncology, and molecular therapy. In 2024, following an operational assessment in 2023, CureVac implemented an organizational restructuring to concentrate resources on high-value mRNA opportunities in oncology, infectious diseases, and other areas with significant unmet medical needs. This redesign involves streamlining structures and reducing operating costs across most business areas to increase efficiency and performance. The restructuring began in April 2024 with a voluntary leaver program to reduce approximately 150 positions. A second voluntary leaver program was initiated in August 2024, targeting an overall workforce reduction of approximately 30% in 2024. The 2024 GSK Agreement, which includes an upfront payment of 400 million and up to 1.05 billion in milestones plus tiered royalties, provided substantial financing and supported the streamlining of operations.